Dimensional Fund Advisors
IOVA icon

Dimensional Fund Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Dimensional Fund Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.9M Buy
6,460,449
+3,814,747
+144% +$14.5M ﹤0.01% 1906
2026
Q1 		$9.28M Buy
2,645,702
+1,106,592
+72% +$3.54M ﹤0.01% 2278
2025
Q4 		$4.2M Sell
1,539,110
-1,283,648
-45% -$2.97M ﹤0.01% 2577
2025
Q3 		$6.13M Sell
2,822,758
-105,978
-4% -$250K ﹤0.01% 2481
2025
Q2 		$5.04M Sell
2,928,736
-577,372
-16% -$1.44M ﹤0.01% 2519
2025
Q1 		$11.7M Buy
3,506,108
+1,075,887
+44% +$5.55M ﹤0.01% 2182
2024
Q4 		$18M Buy
2,430,221
+360,629
+17% +$3.34M ﹤0.01% 2034
2024
Q3 		$19.4M Sell
2,069,592
-195,963
-9% -$1.86M ﹤0.01% 2015
2024
Q2 		$18.2M Sell
2,265,555
-605,943
-21% -$6.49M ﹤0.01% 2005
2024
Q1 		$42.6M Sell
2,871,498
-645,489
-18% -$7.51M 0.01% 1575
2023
Q4 		$28.6M Sell
3,516,987
-461,398
-12% -$2.41M 0.01% 1799
2023
Q3 		$18.1M Buy
3,978,385
+1,881,382
+90% +$12.3M 0.01% 1980
2023
Q2 		$14.8M Buy
2,097,003
+587,770
+39% +$4.21M ﹤0.01% 2076
2023
Q1 		$9.22M Buy
+1,509,233
New +$10.4M ﹤0.01% 2266
2022
Q3 		$15.9M Buy
1,662,513
+415,153
+33% +$4.79M 0.01% 1946
2022
Q2 		$13.8M Buy
1,247,360
+72,896
+6% +$955K ﹤0.01% 2062
2022
Q1 		$19.6M Buy
1,174,464
+289,983
+33% +$4.48M 0.01% 1982
2021
Q4 		$16.9M Buy
884,481
+553,559
+167% +$12.2M 0.01% 2074
2021
Q3 		$8.16M Buy
330,922
+156,628
+90% +$3.69M ﹤0.01% 2417
2021
Q2 		$4.54M Sell
174,294
-16,856
-9% -$438K ﹤0.01% 2641
2021
Q1 		$6.04M Buy
191,150
+52,425
+38% +$2.17M ﹤0.01% 2507
2020
Q4 		$6.44M Buy
138,725
+40,816
+42% +$1.62M ﹤0.01% 2438
2020
Q3 		$3.22M Buy
97,909
+30,894
+46% +$947K ﹤0.01% 2598
2020
Q2 		$1.84M Sell
67,015
-403,236
-86% -$13.3M ﹤0.01% 2785
2020
Q1 		$14.1M Sell
470,251
-304,740
-39% -$8.08M 0.01% 1942
2019
Q4 		$21.5M Sell
774,991
-39,528
-5% -$899K 0.01% 2010
2019
Q3 		$14.8M Sell
814,519
-1,420
-0.2% -$31.4K 0.01% 2169
2019
Q2 		$20M Buy
815,939
+458,811
+128% +$6.91M 0.01% 2051
2019
Q1 		$3.4M Hold
357,128
– – ﹤0.01% 2765
2018
Q4 		$3.16M Buy
357,128
+326,531
+1,067% +$3.15M ﹤0.01% 2729
2018
Q3 		$344K Buy
+30,597
New +$434K ﹤0.01% 3234

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Dimensional Fund Advisors's IOVA Position: Q2 2026 in Review

Dimensional Fund Advisors increased its Iovance Biotherapeutics (IOVA) stake by 144% in Q2 2026, buying an estimated $14.5M and bringing the position to 6,460,449 shares worth $26.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1906.

Dimensional Fund Advisors first reported a position in IOVA in Q3 2018 and has held it in 31 quarters since. The position peaked at $42.6M in Q1 2024. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Dimensional Fund Advisors held 6,460,449 shares of Iovance Biotherapeutics worth $26.9M as of Q2 2026.
  • Dimensional Fund Advisors bought 3,814,747 Iovance Biotherapeutics shares in Q2 2026, an estimated $14.5M.
  • Iovance Biotherapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #1906 holding.
  • Dimensional Fund Advisors first reported a position in Iovance Biotherapeutics in Q3 2018 and has held it in 31 quarters since.
  • Dimensional Fund Advisors's Iovance Biotherapeutics position peaked at $42.6M in Q1 2024.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.